IP Library Granted Patent US 11,213,495
Granted Patent B2
US 11,213,495 · App. 16/304,217 · Granted Jan 4, 2022

Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine

Inventor: Hwei-Hsien Chen (Zhunan Town, TW)
Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
A61K31/135A61K31/205A61P25/24A61P25/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,213,495
App. No.
16/304,217
Granted
Jan 4, 2022
Kind
B2
Abstract

The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative.

Claims (8)

1. An antidepressant composition, comprising ketamine in an effective amount of treating depression and betaine in an effective amount of preventing or treating an addictive disorder or reducing the psychotomimetic side effect of ketamine.

2. The composition of claim 1 , wherein the composition is in an amount for treating depressive symptoms in a patient with schizophrenia.

3. The composition of claim 1 , wherein betaine is in an effective amount of antagonizing a psychotomimetic side effect of ketamine.

4. The composition of claim 1 , wherein the composition is in an effective amount for preventing or treating treatment-resistant depression.

5. A method for treating depression in a subject in need thereof, comprising administering an effective amount of an antidepressant composition of claim 1 to the subject.

6. The method of claim 5 , wherein the subject is a schizophrenic patient with depression.

7. The method of claim 5 , wherein the subject is a patient with treatment-resistant depression.

8. The method of claim 5 , wherein the subject is a patient with ketamine addictive disorders.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: KUNG, HSING-JIEN; NATIONAL HEALTH RESEARCH INSTITUTES
To: NATIONAL HEALTH RESEARCH INSTITUTES
Reel/Frame 052263/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: CHEN, HWEI-HSIEN
To: NATIONAL HEALTH RESEARCH INSTITUTES; KUNG, HSING-JIEN
Reel/Frame 048192/0700 →
Continuity (2)
Provisional Application 62341278 · May 25, 2016
Related Publication 20200069610A1 · Mar 5, 2020
Cited By (1)
US 12,440,440